drug_type
RELEVANT_DRUG
intervention_type
Biological (autologous CAR T-cell therapy)
drug_description
Autologous, genetically engineered chimeric antigen receptor T-cell therapy in which patient T cells are modified to express CARs targeting CLL1 (CLEC12A) and CD33; antigen engagement activates T cells to induce cytotoxic killing of AML cells. Administered as a single IV infusion (approximately 1.0–2.5×10^6 CAR+ T cells/kg).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express chimeric antigen receptors that recognize CLL1 (CLEC12A) and CD33 on AML cells; antigen engagement activates CAR signaling independent of the native TCR, driving T‑cell activation, proliferation, cytokine release, and cytotoxic killing of AML blasts and leukemic stem/progenitor cells expressing either antigen.
drug_name
CLL1/+CD33 CAR-T
nct_id_drug_ref
NCT05943314